Company Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Country | United Kingdom |
| Founded | 1992 |
| IPO Date | May 12, 1993 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 89,900 |
| CEO | Pascal Soriot |
Contact Details
Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus Cambridge, CB2 0AA United Kingdom | |
| Phone | 44 20 3749 5000 |
| Website | astrazeneca.com |
Stock Details
| Ticker Symbol | AZN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000901832 |
| CUSIP Number | 046353108 |
| ISIN Number | US0463531089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pascal Soriot | Chief Executive Officer |
| Aradhana Sarin | Chief Financial Officer |
| Pam Cheng | Chief Operating Officer |
| Andrew Barnett | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | 6-K | Report of foreign issuer |
| Dec 23, 2024 | 6-K | Report of foreign issuer |
| Dec 16, 2024 | 6-K | Report of foreign issuer |
| Dec 5, 2024 | 6-K | Report of foreign issuer |
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 6-K | Report of foreign issuer |
| Nov 25, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |